Bull Run
Financial RatiosPE RatioShareholdingDividendQuarterly ResultsFinancial Statements

Zealand Pharma A/S Stock Price Today (NSE: ZEAL)

Zealand Pharma A/S

ZEALLogistics Solution Provider
₹73.25+₹0.00 (+0.00%)
Market Closed

Fundamental Score

...

Zealand Pharma A/S Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Zealand Pharma A/S share price today is ₹73.25, up +0.00% on NSE/BSE as of 18 June 2026. Zealand Pharma A/S (ZEAL) is a Small-cap company in the Logistics Solution Provider sector with a market capitalisation of ₹132.43 (Cr). The 52-week high for ZEAL share price is ₹141.00 and the 52-week low is ₹55.90. At a P/E ratio of 13.23x, ZEAL is currently trading below its industry average P/E of 25.23x. The company has a Return on Equity (ROE) of 19.60% and a debt-to-equity ratio of 0.29.

Zealand Pharma A/S Share Price Chart — NSE/BSE Historical Performance

No data
High
₹97.00
Low
₹56.20
Volume
5.4K
Change
+27.84%

Zealand Pharma A/S share price chart: 27.84% return over the past month. 52-week high ₹141.00, 52-week low ₹55.90.

Zealand Pharma A/S — Last 10 Trading Days

DateOpenHighLowCloseVolume
₹73.25₹73.25₹73.25₹73.250.00 (Cr)
₹72.20₹73.25₹69.00₹73.2510.20K (Cr)
₹75.00₹75.00₹71.15₹72.104.20K (Cr)
₹76.00₹76.00₹76.00₹76.001.20K (Cr)
₹74.50₹75.15₹70.05₹74.704.80K (Cr)
₹79.00₹79.00₹68.00₹72.1517.40K (Cr)
₹85.00₹85.00₹75.50₹79.009.60K (Cr)
₹88.00₹89.00₹83.15₹86.051.80K (Cr)
₹92.65₹92.65₹90.00₹90.001.20K (Cr)
₹80.00₹97.00₹80.00₹89.857.80K (Cr)

Zealand Pharma A/S — Last 12 Months Price History

MonthOpenHighLowCloseChange
₹59.95₹97.00₹59.95₹73.25+22.19%
₹70.80₹77.00₹55.90₹57.30-19.07%
₹71.50₹90.40₹71.25₹79.50+11.19%
₹90.05₹95.00₹72.00₹72.00-20.04%
₹100.05₹101.80₹91.50₹94.00-6.05%
₹108.00₹121.40₹99.15₹102.95-4.68%
₹116.45₹120.90₹101.00₹106.95-8.16%
₹117.20₹124.75₹103.00₹112.00-4.44%
₹124.30₹126.00₹116.00₹118.00-5.07%
₹135.00₹141.00₹120.00₹125.55-7.00%
₹139.50₹141.20₹130.00₹132.75-4.84%

AI Research Briefing

Powered by Gemini · 2026-04-10

Obesity drug pipeline is a binary bet; success brings riches, failure brings ruin.

Research Confidence
6.0/10Moderate
WAR NARRATIVE TRADEPrice is down 28.26% over the last 6 months, indicating a downtrend.Industry P/E is 25.23x vs P/E of 13.23x, appearing cheap, but biotech valuations are pipeline-driven.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Zealand Pharma increased its share capital by DKK 10,530 on March 19, 2026, due to employee warrants being exercised at DKK 90.70 per share, raising total proceeds of DKK 955,071. The Annual General Meeting on March 26, 2026, approved all proposals except the non-binding advisory vote on the remuneration report. Zealand Pharma also established a U.S. Research Hub in Cambridge, Massachusetts, to expand drug discovery capabilities.

CORE STORY (THE REAL GAME)

Zealand Pharma is an obesity and metabolic health play, driven by its peptide R&D expertise and AI/ML platform, aiming to become a leader in the next wave of metabolic health innovation.

Why Now
  • Upcoming Phase 3 Survodutide data in H1 2026
  • Potential USD 700M milestone payment from Roche in 2026
  • Establishment of US research hub signals commitment to innovation
Potential Catalysts
  • Positive Phase 3 Survodutide results
  • Successful Phase 2 Petrelintide data
  • New partnership or acquisition in metabolic health
Key Risks
  • Micro-cap liquidity risk
  • Clinical trial failure risk
  • Reliance on Roche collaboration
Institutional Activity

DII increased stake by 1.8% (small base)

Macro Context

Increasing demand for obesity treatments provides a strong tailwind.

Cash Flow Quality

Negative Free Cash Flow of ₹-5.07 Cr over the last 5 years.

3–6 Month Outlook

3-6 month thesis hinges on clinical trial data releases. Positive results will drive a re-rating; negative results will lead to a significant sell-off.

Primary Thesis Risk

Clinical trial failure will obliterate the obesity pipeline thesis.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Excellent

Return on Equity (ROE)

19.60%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

23.80%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

7.56%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Zealand Pharma A/S Valuation Check

Excellent

Price to Earnings (P/E)

13.23x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

25.23x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

73.40%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

2.19%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-49.73%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

0.56%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

36.90%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-12.34%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

62.94%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.29x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

8.56x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-5.07 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Zealand Pharma A/S Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ZEAL across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Return on Equity (19.60%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (23.80%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 13.23 vs Industry: 25.23)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Consistent Growth Track Record (36.90% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Strong Profit Growth Track Record (62.94% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.29)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (8.56x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (73.40%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Profit Decline Concern (-49.73%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Weak Earnings Growth (-12.34% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Negative Free Cash Flow (₹-5.07 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 2.19%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Zealand Pharma A/S vs Logistics Solution Provider Peers

Peer Comparison - Logistics Solution Provider

Compare Zealand Pharma A/S with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
Zealand Pharma ...✓
ZEAL •
51.7/100
₹73
₹132.43
13.2
Average
19.60%
Good
23.80%
Excellent
0.3
Excellent
62.94%
Excellent
36.90%
Excellent
0.00%
Container Corpo...
CONCOR • 531344
41.1/100
₹472
₹38511.34
29.4
Average
10.79%
Average
13.87%
Average
0.1
Excellent
7.10%
Good
6.36%
Good
1.82%
Delhivery Ltd...
DELHIVERY • 543529
29.5/100
₹460
₹31216.18
225.8
Average
1.52%
Poor
2.47%
Poor
0.2
Excellent
19.71%
Excellent
26.29%
Excellent
0.00%
Blue Dart Expre...
BLUEDART • 526612
60.6/100
₹4773
₹13389.23
50.3
Average
16.19%
Good
16.33%
Good
0.7
Good
46.19%
Excellent
12.49%
Good
0.44%
Transport Corpo...
TCI • 532349
58/100
₹904
₹8288.71
19.1
Average
19.79%
Good
20.52%
Excellent
0.1
Excellent
22.20%
Excellent
10.57%
Good
0.74%
TVS Supply Chai...
TVSSCS • 543965
22.5/100
₹121
₹4837.99
40.8
Average
-0.72%
Poor
4.83%
Poor
1.1
Average
14.06%
Good
8.64%
Good
0.00%
VRL Logistics L...
VRLLOG • 539118
47.9/100
₹248
₹4768.78
20.4
Average
17.44%
Good
15.73%
Good
1.0
Average
13.71%
Good
8.33%
Good
2.75%
Sindhu Trade Li...
SINDHUTRAD • 532029
27.5/100
₹27
₹3626.66
—
0.35%
Poor
5.45%
Poor
0.3
Excellent
15.49%
Excellent
8.04%
Good
0.00%
Mahindra Logist...
MAHLOG • 540768
22.9/100
₹349
₹3225.36
—
-7.96%
Poor
5.64%
Poor
0.6
Good
—
11.95%
Good
0.77%
Gateway Distrip...
GATEWAY • 543489
50.2/100
₹57
₹2872.90
11.5
Average
12.24%
Average
10.65%
Average
0.3
Excellent
21.69%
Excellent
5.40%
Good
3.48%
Tci Express Ltd...
TCIEXP • 540212
35.9/100
₹510
₹2276.19
26.0
Average
11.96%
Average
15.79%
Good
0.0
Excellent
-0.26%
Poor
3.20%
Average
1.35%

Top Logistics Solution Provider Stocks

View all →

Zealand Pharma A/S PE Ratio History

Historical price-to-earnings ratio for ZEAL — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 2023₹7.40₹215.0029x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Zealand Pharma A/S Dividend History

Annual cash dividends paid by ZEAL — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 2024₹1.33 Cr
FY 2021₹0.02 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Zealand Pharma A/S Quarterly Performance

Latest quarterly metrics for ZEAL — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

0.56%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-49.73%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

36.90%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

62.94%

Compounded annual net profit growth over 5 years

Zealand Pharma A/S Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ZEAL — calculated from daily price history

45RSI 14
Neutral — RSI 45

Momentum is balanced — neither overbought nor oversold.

SMA 50
₹74
▼ Price below SMA 50 — Short-term bearish
SMA 200
₹99
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
7K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Zealand Pharma A/S Financial Statements

Annual income statement, balance sheet and cash flow for Zealand Pharma A/S (ZEAL) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Zealand Pharma A/S

About ZEAL (Zealand Pharma A/S)

Zealand Pharma A/S (ZEAL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Logistics Solution Provider sector wi...th a current market capitalisation of ₹132.43 (Cr). Zealand Pharma A/S has delivered a Return on Equity (ROE) of 19.60% and a ROCE of 23.80%. The debt-to-equity ratio stands at 0.29, reflecting the company's capital structure. Investors tracking ZEAL share price can monitor key metrics including P/E ratio, promoter holding of 73.40%, and quarterly earnings growth.

Company Details

Symbol:ZEAL
Industry:Logistics Solution Provider
Sector:Logistics Solution Provider
Website:N/A

ZEAL Share Price: Frequently Asked Questions

What is the current share price of Zealand Pharma A/S?

Zealand Pharma A/S (ZEAL) trades at ₹73.25 on NSE. Market cap ₹132.43 (Cr). Educational data only.

What is the P/E ratio of Zealand Pharma A/S?

Zealand Pharma A/S has a P/E of 13.23x vs industry average 25.23x.

What is the Bull Run score for Zealand Pharma A/S?

Zealand Pharma A/S has a Bull Run score of 51.7/100 based on 25+ financial parameters.

Does Zealand Pharma A/S pay dividends?

Zealand Pharma A/S has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Zealand Pharma A/S?

Zealand Pharma A/S has ROE of 19.60%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Zealand Pharma A/S?

Zealand Pharma A/S has debt-to-equity of 0.29.

Is Zealand Pharma A/S a good investment?

Bull Run gives Zealand Pharma A/S a score of 51.7/100. This is not investment advice — consult a SEBI-registered advisor.